Cyclin-dependent kinase-9: an RNAPII kinase at the nexus of cardiac growth and death cascades.
Over the past decade and a half, the paradigm has emerged of cardiac hypertrophy and ensuing heart failure as fundamentally a problem in signal transduction, impinging on the altered expression or function of gene-specific transcription factors and their partners, which then execute the hypertrophic phenotype. Strikingly, RNA polymerase II (RNAPII) is itself a substrate for two protein kinases-the cyclin-dependent kinases Cdk7 and Cdk9--that are activated by hypertrophic cues. Phosphorylation of RNAPII in the carboxyl terminal domain (CTD) of its largest subunit controls a number of critical steps subsequent to transcription initiation, among them enabling RNAPII to overcome its stalling in the promoter-proximal region and to engage in efficient transcription elongation. Here, we summarize our current understanding of the RNAPII-directed protein kinases in cardiac hypertrophy. Cdk9 activation is essential in tissue culture for myocyte enlargement and sufficient in transgenic mice for hypertrophy to occur and yet is unrelated to the "fetal" gene program that is typical of pathophysiological heart growth. Although this trophic effect of Cdk9 appears benign superficially, pathophysiological levels of Cdk9 activity render myocardium remarkably susceptible to apoptotic stress. Cdk9 interacts adversely with Gq-dependent pathways for hypertrophy, impairing the expression of numerous genes for mitochondrial proteins, and, in particular, suppressing master regulators of mitochondrial biogenesis and function, perioxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1), and nuclear respiratory factor-1 (NRF-1). Given the dual transcriptional roles of Cdk9 in hypertrophic growth and mitochondrial dysfunction, we suggest the potential usefulness of Cdk9 as a target in heart failure drug discovery.
Sano
Motoaki
M
Center for Cardiovascular Development, Baylor College of Medicine, Houston, TX 77030, USA.
Schneider
Michael D
MD
D000595:Amino Acid Sequence; D000818:Animals; D017209:Apoptosis; D006332:Cardiomegaly / Q000201:enzymology / Q000235:genetics / Q000473:pathology / Q000517:prevention & control; D048429:Cell Size; D002478:Cells, Cultured / Q000166:cytology / Q000201:enzymology; D056906:Cyclin T; D042863:Cyclin-Dependent Kinase 9 / Q000502:physiology*; D018844:Cyclin-Dependent Kinases / Q000737:chemistry; D016213:Cyclins / Q000502:physiology; D015195:Drug Design; D004789:Enzyme Activation; D006801:Humans; D051379:Mice; D008929:Mitochondria, Heart / Q000201:enzymology; D008969:Molecular Sequence Data; D032383:Myocytes, Cardiac / Q000166:cytology / Q000201:enzymology*; D010766:Phosphorylation; D011499:Protein Processing, Post-Translational; D012319:RNA Polymerase II / Q000378:metabolism; D012342:RNA, Small Nuclear / Q000378:metabolism; D016415:Sequence Alignment; D017386:Sequence Homology, Amino Acid; D014157:Transcription Factors / Q000378:metabolism; D014158:Transcription, Genetic / Q000502:physiology
C503684:CCNT1 protein, human; C503685:Ccnt1 protein, mouse; D056906:Cyclin T; D016213:Cyclins; D012342:RNA, Small Nuclear; D014157:Transcription Factors; C111264:peroxisome-proliferator-activated receptor-gamma coactivator-1; C467969:CDK9 protein, human; C467972:Cdk9 protein, mouse; D042863:Cyclin-Dependent Kinase 9; D018844:Cyclin-Dependent Kinases; D012319:RNA Polymerase II